Article
Biochemistry & Molecular Biology
Hiroko Ishii, Maram H. Zahra, Atushi Takayanagi, Masaharu Seno
Summary: The study developed a novel anti-Cripto-1 artificial antibody by isolating single chain antibody clones, fusing genes, and expressing and purifying the antibody, demonstrating its potential in suppressing the growth of cancer stem cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Immunology
Xiaolei Liu, Li Li, Qian Wang, Fengchao Jiang, Pei Zhang, Fei Guo, Hongjun Liu, Jian Huang
Summary: A new humanized anti-IL-6 mAb HZ-0408b with potent binding and neutralizing activity to human IL-6 has been developed. It showed a high species specificity and lower cross-reactivity compared to other anti-IL-6 mAbs. HZ-0408b exhibited a stronger inhibitory effect on IL-6 signaling and effectively reduced joint swelling and plasma CRP levels in a monkey CIA model.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Jingyi Peng, Jiaguo Wu, Ning Shi, Hua Xu, Longlong Luo, Jing Wang, Xinying Li, He Xiao, Jiannan Feng, Xia Li, Lihui Chai, Chunxia Qiao
Summary: In this study, a novel anti-abrin neutralizing antibody (S008) was humanized using computer-aided design and shown to have a protective effect against abrin both in vitro and in vivo. The results demonstrate that S008 is a potential excellent candidate for clinical treatment of abrin poisoning.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Pei-Hua Lin, Chi-Ling Tseng, Yun-Chih Cheng, Chieh-Hsin Ho, Shih Chieh Chen, Yanling Wang, Eugene Liu, Hassan Issafras, Weidong Jiang
Summary: HLX07, produced by re-engineering cetuximab through humanizing its Fab regions and reducing glycan contents, shows similar affinity to EGFR as cetuximab but better bioactivity in vitro. In vivo studies demonstrate that HLX07 significantly inhibits the growth of various tumor cells and synergizes with chemotherapeutics and immune simulator agents. Toxicokinetic studies in cynomolgus monkeys and dose-escalation study in humans show promising safety profile compared to cetuximab.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2021)
Article
Oncology
Ming-Mo Hou, Ching-Liang Ho, Hsuan-Yu Lin, Yunting Zhu, Xiaodi Zhang
Summary: The study evaluated the safety and pharmacokinetic profiles of HLX07 in patients with advanced solid cancers. A total of 19 patients received HLX07 at doses ranging from 50 to 800 mg/week, with common adverse events including fatigue, nausea, paronychia, and vomiting. Systemic exposure to HLX07 increased proportionally with dose, and the drug was well tolerated up to a dose of 800 mg/week in these patients.
INVESTIGATIONAL NEW DRUGS
(2021)
Article
Oncology
Seung Won Choi, Hyun Ae Jung, Hee-Jin Cho, Tae Min Kim, Chul-Kee Park, Do-Hyun Nam, Se-Hoon Lee
Summary: This study evaluated the therapeutic efficacy of the novel anti-EGFR monoclonal antibody GC1118 in recurrent GBM patients with EGFR amplification. Although the study did not meet the primary endpoint, it was found that immune-related signatures were significantly upregulated in tumors with regression upon GC1118 therapy, indicating the potential immune-mediated antitumor efficacy of GC1118.
Article
Immunology
Lei Chen, Jiansheng Lu, Junjie Yue, Rong Wang, Peng Du, Yunzhou Yu, Jiazheng Guo, Xi Wang, Yujia Jiang, Kexuan Cheng, Zhixin Yang, Tao Zheng
Summary: A humanized monoclonal antibody 9-8-h2, derived from mice immunization, showed potent neutralization activity against HAdV55. It recognized a conformational neutralization epitope and had favorable physicochemical properties. It could be a promising molecule for the prevention and treatment of HAdV55.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Jafar Sharifi, Mohammad Reza Khirehgesh, Bahman Akbari, Bijan Soleymani, Kamran Mansouri
Summary: Targeted therapy is an effective approach in cancer treatment, and a novel humanized anti-EGFR biparatopic nanobody, hu7CG2, showed potential in inhibiting the growth of EGFR-overexpressing tumor cells by grafting specific regions from camelid anti-EGFR nanobodies.
MOLECULAR BIOTECHNOLOGY
(2021)
Article
Medicine, Research & Experimental
Guojuan Miao, Xiuhong Sun
Summary: An immunomodulatory antibody targeting B7-H4 was successfully generated, showing inhibitory activity on T cell immune suppression and ADCC activity in B7-H4-positive tumors. This antibody could potentially serve as a promising immunotherapy for B7-H4-expressing tumors.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Immunology
Juliette Rousse, Pierre-Joseph Royer, Gwenaelle Evanno, Elsa Lheriteau, Carine Ciron, Apolline Salama, Francoise Shneiker, Roberto Duchi, Andrea Perota, Cesare Galli, Emmanuele Cozzi, Gilles Blancho, Odile Duvaux, Sophie Brouard, Jean-Paul Soulillou, Jean-Marie Bach, Bernard Vanhove
Summary: Anti-thymocyte or anti-lymphocyte globulins (ATGs/ALGs) are immunosuppressive drugs used in solid organ transplantation to prevent acute rejection. The glyco-humanized ALG (GH-ALG) can efficiently inhibit T-cell alloreactivity and reduce the risk for allograft rejection in non-human primates.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Adrian Esqueda, Haiyan Sun, James Bonner, Huafang Lai, Collin Jugler, Karen V. V. Kibler, Herta Steinkellner, Qiang Chen
Summary: The development of glycovariants of 7D11, a neutralizing monoclonal antibody, produced in plants, shows promise as a potential therapeutic against the current monkeypox virus (MPXV) outbreak. The plant-made 7D11 antibody quickly accumulates to high levels and can be easily purified. It retains specific binding to its antigen and displays strong neutralization activity against MPXV, similar to its activity against vaccinia virus.
Article
Biochemistry & Molecular Biology
Dan-dan Zhou, Li-ping Sun, Qun Yu, Xiao-tian Zhai, Lan-wen Zhang, Rui-juan Gao, Yong-su Zhen, Rong Wang, Qing-fang Miao
Summary: The novel anti-Trop2 antibody IMB1636 exhibited high affinity and specificity in binding antigens, cancer cells, and human tumor tissues. It induced endocytosis and targeted delivery to the tumor site. The humanized antibody hIMB1636 showed potential in inhibiting cancer cell proliferation and migration, and inducing ADCC effects. Moreover, hIMB1636 significantly inhibited tumor growth in vivo.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)
Article
Oncology
Ying Gong, Roel G. J. Klein Wolterink, Valeriia Gulaia, Silvie Cloosen, Femke A. I. Ehlers, Lotte Wieten, Yvo F. Graus, Gerard M. J. Bos, Wilfred T. V. Germeraad
Summary: The study describes a novel fully humanized anti-MUC1 antibody, which, especially after defucosylation, is a promising therapeutic candidate for cellular immunotherapy.
Article
Oncology
Laura Rubio-Perez, Rodrigo Lazaro-Gorines, Seandean L. Harwood, Marta Compte, Rocio Navarro, Antonio Tapia-Galisteo, Jaume Bonet, Belen Blanco, Simon Lykkemark, Angel Ramirez-Fernandez, Mariola Ferreras-Gutierrez, Carmen Dominguez-Alonso, Laura Diez-Alonso, Alejandro Segura-Tudela, Oana Hangiu, Ainhoa Erce-Llamazares, Francisco J. Blanco, Cruz Santos, Jose L. Rodriguez-Peralto, Laura Sanz, Luis Alvarez-Vallina
Summary: In this study, a PD-L1/EGFR symmetric bispecific antibody was developed, which could simultaneously inhibit EGFR-mediated proliferation, effectively block PD-1/PD-L1 interaction, and induce strong antigen-specific antibody-dependent cellular cytotoxicity activity in vitro. Potent therapeutic efficacies of this antibody were observed in two different humanized mouse models.
Article
Surgery
Ryo Hatano, Takumi Itoh, Haruna Otsuka, Harumi Saeki, Ayako Yamamoto, Dan Song, Yuki Shirakawa, Satoshi Iyama, Tsutomu Sato, Noriaki Iwao, Norihiro Harada, Thomas M. Aune, Nam H. Dang, Yutaro Kaneko, Taketo Yamada, Chikao Morimoto, Kei Ohnuma
Summary: IL-26 has immunological effects in chronic GVHD models, promoting disease progression and increasing neutrophil levels. It upregulates Th17 cytokines and enhances the expression of granulocyte-colony stimulating factor, IL-1 beta, and IL-6. The use of an anti-IL-26 monoclonal antibody can mitigate weight loss and prolong survival in chronic xenogeneic-GVHD.
AMERICAN JOURNAL OF TRANSPLANTATION
(2022)
